

# Rik J Verheijden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8122258/publications.pdf>

Version: 2024-02-01

7  
papers

221  
citations

1684188

5  
h-index

1720034

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

297  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-Reported Outcomes During Checkpoint Inhibition: Insight into Symptom Burden in Daily Clinical Practice. <i>Journal of Pain and Symptom Management</i> , 2022, 63, 997-1005.	1.2	5
2	Frailty and checkpoint inhibitor toxicity in older patients with melanoma. <i>Cancer</i> , 2022, 128, 2746-2752.	4.1	12
3	TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out. <i>Nature Reviews Rheumatology</i> , 2021, 17, 505-505.	8.0	5
4	Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. <i>ESMO Open</i> , 2020, 5, e000945.	4.5	14
5	Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2020, 6, 1300.	7.1	4
6	Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. <i>Clinical Cancer Research</i> , 2020, 26, 2268-2274.	7.0	112
7	Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review. <i>Frontiers in Oncology</i> , 2020, 10, 585311.	2.8	69